Acute exacerbations of myasthenia gravis (MG) need effective and urgent treatment because of life-threatening hypoventilation. Plasma exchange and intravenous immunoglobulin (IVIg) are both effective for acute MG. A new study suggests that these treatments produce similar patient outcomes and complications, with IVIg perhaps being superior from an economic perspective.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Skeie, G. O. et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur. J. Neurol. 17, 893–902 (2010).
Jani-Acsadi, A. & Lisak, R. P. Myasthenia gravis. Curr. Treat. Options Neurol. 12, 231–243 (2010).
Mandawat, A., Kaminski, H. J., Cutter, G., Katirji, B. & Alsheklee, A. Comparative analysis of therapeutic options used for myasthenia gravis. Ann. Neurol. 68, 797–805 (2010).
Owe, J. F., Daltveit, A. K. & Gilhus, N. E. Causes of death among patients with myasthenia gravis in Norway between 1951 and 2001. J. Neurol. Neurosurg. Psychiat. 77, 203–207 (2006).
Gilhus, N. E. Autoimmune myasthenia gravis. Expert Rev. Neurother. 9, 351–358 (2009).
Cabrera Serrano, M. & Rabinstein, A. A. Causes and outcomes of acute neuromuscular respiratory failure. Arch. Neurol. 67, 1089–1094 (2010).
Gajdos, P., Chevret, S. & Toyka, K. V. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database of Systematic Reviews Issue 1, Art. No.: CD002277. doi: 10.1002/14651858.CD002277.pub3 (2008).
Simoens, S. The use of intravenous immunoglobulins in Belgium. Int. Arch. Allergy Immunol. 154, 173–176 (2011).
Elovaara, I. et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases. Eur. J. Neurol. 15, 893–908 (2008).
Alshekhlee, A., Miles, J. D., Katirji, B., Preston, D. C. & Kaminski, H. J. Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals. Neurology 72, 1548–1554 (2009).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Gilhus, N. Acute treatment for myasthenia gravis. Nat Rev Neurol 7, 132–134 (2011). https://doi.org/10.1038/nrneurol.2011.14
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2011.14
This article is cited by
-
Myasthenia gravis — autoantibody characteristics and their implications for therapy
Nature Reviews Neurology (2016)